# A Combined SAD and MAD Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of IFB-088

> **NCT03610334** · PHASE1 · COMPLETED · sponsor: **InFlectis BioScience** · enrollment: 72 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** IFB-088 (2.5-60.0mg) oral capsule
- **DRUG:** Placebo (2.5-60.mg) oral capsule
- **DRUG:** IFB-088 (15.0-50.0mg) oral capsule
- **DRUG:** Placebo oral (15.0-50.0mg) capsule

## Key facts

- **NCT ID:** NCT03610334
- **Lead sponsor:** InFlectis BioScience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-21
- **Primary completion:** 2019-06-21
- **Final completion:** 2019-12-16
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2022-01-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03610334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03610334, "A Combined SAD and MAD Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of IFB-088". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03610334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*